A detailed history of Nomura Asset Management CO LTD transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Nomura Asset Management CO LTD holds 18,000 shares of ASND stock, worth $2.45 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
18,000
Previous 12,629 42.53%
Holding current value
$2.45 Million
Previous $1.72 Million 56.1%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$113.0 - $153.43 $606,923 - $824,072
5,371 Added 42.53%
18,000 $2.69 Million
Q2 2024

Aug 14, 2024

SELL
$121.07 - $153.67 $157,391 - $199,770
-1,300 Reduced 9.33%
12,629 $1.72 Million
Q1 2024

May 13, 2024

BUY
$123.45 - $159.4 $155,670 - $201,003
1,261 Added 9.95%
13,929 $2.11 Million
Q3 2023

Nov 03, 2023

SELL
$86.5 - $103.97 $150,856 - $181,323
-1,744 Reduced 12.1%
12,668 $1.19 Million
Q2 2023

Aug 14, 2023

BUY
$69.96 - $97.84 $76,536 - $107,036
1,094 Added 8.21%
14,412 $1.29 Million
Q1 2023

May 11, 2023

BUY
$104.9 - $126.78 $67,975 - $82,153
648 Added 5.11%
13,318 $1.43 Million
Q2 2022

Aug 12, 2022

BUY
$78.08 - $117.61 $69,491 - $104,672
890 Added 7.56%
12,670 $1.18 Million
Q1 2022

May 13, 2022

BUY
$102.18 - $135.75 $116,485 - $154,755
1,140 Added 10.71%
11,780 $1.38 Million
Q4 2021

Feb 01, 2022

BUY
$127.1 - $169.66 $206,156 - $275,188
1,622 Added 17.99%
10,640 $1.43 Million
Q3 2021

Nov 12, 2021

BUY
$112.67 - $176.92 $100,952 - $158,520
896 Added 11.03%
9,018 $1.44 Million
Q1 2021

May 14, 2021

BUY
$124.92 - $173.33 $1.01 Million - $1.41 Million
8,122 New
8,122 $1.05 Million
Q4 2020

Feb 12, 2021

BUY
$151.2 - $182.76 $0 - $0
0 New
0 $0
Q3 2020

Nov 12, 2020

BUY
$134.29 - $154.32 $0 - $0
0 New
0 $0

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.61B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Nomura Asset Management CO LTD Portfolio

Follow Nomura Asset Management CO LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Asset Management CO LTD, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Asset Management CO LTD with notifications on news.